Head-to-head · Cost-Efficiency Index
NextMeds vs Direct Meds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NextMeds
Shoppers who will call out and verify the exact price at checkout, given the site shows several different promo numbers at once.
Visit NextMedsDirect Meds
Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold.
Visit Direct MedsThe verdict
NextMeds takes it, leading the Cost-Efficiency Index 74 to 71. NextMeds is a compounded-GLP-1 telehealth platform naming a real clinical group (Lion MD, led by two NPI-verifiable physicians) and six named compounding pharmacies — unusually transparent on that front. Direct Meds still earns a C — Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NextMeds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NextMeds | Direct Meds |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 71/100 |
| Semaglutide / mo | $79/mo (starting dose, promotional rate, compounded) | $249/mo (sublingual, 90-day supply billed monthly) |
| Tirzepatide / mo | $129/mo (starting dose, promotional rate, compounded) | $299/mo (sublingual, 90-day supply billed monthly) |
| Semaglutide / yr (modeled) | $948 | $2,988 |
| Tirzepatide / yr (modeled) | $1,548 | $3,588 |
| Coverage | All 50 states | Not disclosed |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #61 | #64 |
NextMeds
74/100Where the value is
- Names a real, NPI-verifiable clinical group (Lion MD: Dr. Ana Lisa Carr, Dr. Kelly Tenbrink) rather than an anonymous provider network
- Names six real compounding pharmacies (Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub, Foothills) instead of one generic claim
- Claims and states 'We service all 50 states'
The tradeoffs
- The live site shows at least three different headline promo prices ($69/$79/$89 for semaglutide) concurrently or near-concurrently, with no clear single 'current' number — a real transparency problem
- Aggressive countdown-timer urgency tactics ('Price increases in...', 'OFFER ENDS AUGUST 10TH AT MIDNIGHT!') are used to pressure signup
Direct Meds
71/100Where the value is
- Sublingual AND injection on BOTH molecules — four GLP-1 SKUs, the widest formulation range of any provider in this ranking
- Every price is published per SKU in a public shop, with no quiz, intake or email capture in front of it
- Each product page prints a per-day equivalent beside the monthly rate ($8.03/day at $249), which is unusually concrete for this category
The tradeoffs
- $249/mo sublingual is well above this ranking's ~$144 median, and the injection route is $297 — the cheapest thing here is dearer than most rows' headline price
- The only purchasable option on every product page is a 90-DAY SUPPLY billed monthly, so three months is the smallest unit sold — there is no month-to-month rate to compare against the rows beside it
Regulatory note: the FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025. We still list and link to Direct Meds; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.